DK1097167T3 - Neurotrofisk vækstfaktor - Google Patents

Neurotrofisk vækstfaktor

Info

Publication number
DK1097167T3
DK1097167T3 DK99938261T DK99938261T DK1097167T3 DK 1097167 T3 DK1097167 T3 DK 1097167T3 DK 99938261 T DK99938261 T DK 99938261T DK 99938261 T DK99938261 T DK 99938261T DK 1097167 T3 DK1097167 T3 DK 1097167T3
Authority
DK
Denmark
Prior art keywords
growth factor
neurotrophic growth
bioprecursor
organism
derivative
Prior art date
Application number
DK99938261T
Other languages
Danish (da)
English (en)
Inventor
Hugo Alfonso Geerts
Stefan Leo Jozef Masure
Theo Frans Meert
Miroslav Cik
Donck Luc August Laurentiu Ver
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27269394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1097167(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9815283.8A external-priority patent/GB9815283D0/en
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK1097167T3 publication Critical patent/DK1097167T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
DK99938261T 1998-07-14 1999-07-14 Neurotrofisk vækstfaktor DK1097167T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9815283.8A GB9815283D0 (en) 1998-07-14 1998-07-14 Neurotrophic growth factor
US24877299A 1999-02-12 1999-02-12
US32766899A 1999-06-08 1999-06-08
PCT/EP1999/005031 WO2000004050A2 (en) 1998-07-14 1999-07-14 Neurotrophic growth factor

Publications (1)

Publication Number Publication Date
DK1097167T3 true DK1097167T3 (da) 2007-03-12

Family

ID=27269394

Family Applications (2)

Application Number Title Priority Date Filing Date
DK99938261T DK1097167T3 (da) 1998-07-14 1999-07-14 Neurotrofisk vækstfaktor
DK05112473.3T DK1640381T3 (da) 1998-07-14 1999-07-14 Neurotrofisk vækstfaktor

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK05112473.3T DK1640381T3 (da) 1998-07-14 1999-07-14 Neurotrofisk vækstfaktor

Country Status (28)

Country Link
US (1) US7544788B2 (pt)
EP (2) EP1640381B1 (pt)
JP (2) JP4469500B2 (pt)
KR (2) KR100773776B1 (pt)
CN (1) CN1243770C (pt)
AT (1) ATE343594T1 (pt)
AU (1) AU768472B2 (pt)
BG (1) BG65518B1 (pt)
BR (2) BRPI9912819B8 (pt)
CA (1) CA2333910C (pt)
CY (2) CY1105949T1 (pt)
CZ (1) CZ303868B6 (pt)
DE (1) DE69933771T2 (pt)
DK (2) DK1097167T3 (pt)
ES (2) ES2275349T3 (pt)
HK (2) HK1045528B (pt)
HR (1) HRP20010036B1 (pt)
HU (1) HU226073B1 (pt)
ID (1) ID27024A (pt)
IL (1) IL140877A0 (pt)
NO (1) NO331809B1 (pt)
NZ (1) NZ509723A (pt)
PL (1) PL209952B1 (pt)
PT (2) PT1640381E (pt)
SI (1) SI1640381T1 (pt)
SK (1) SK287361B6 (pt)
TR (1) TR200100074T2 (pt)
WO (1) WO2000004050A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9911908A (pt) * 1998-07-06 2001-03-27 Nsgene As ácido nucléico, sequência de ácido nucléico, processos de usar um ácido nucléico, de usar o vetor, de fabricar o polipeptìdeo, de administrar o polipeptìdeo, de tratar uma doença ou distúrbio neurodegenerativos em um animal, de determinar se uma doença ou distúrbio neurodegenerativos em um animal, de produzir qualquer um polipeptìdeo, processo para identificar, isolar ou amplificar uma sequência de ácido nucléico de neublastina, de diagnosticar ou avaliar quanto a presença de uma doença ou distúrbio ou uma predisposiçãopara desnvolvê-los, para avaliar um polipeptìdeo de neublastina purificado ou um derivado ou fragmento deste ou um modulador da atividade dos precedentes quanto a atividade em tratar ou prevenir uma doença, de tratar um distúbio neurológico, de usar a sequência de um ou mais ácidos nucléicos, e para identificar um composto candidato que induza um efeito biológico mediado pela neuroblastina, vetor, célula transformada com ácido nucléico, polipeptìdeo, cmposição, anticorpo, gene sintético, e, conjunto.
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US7067473B1 (en) 1998-07-14 2006-06-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
SK287361B6 (sk) * 1998-07-14 2010-08-09 Janssen Pharmaceutica N. V. Ľudský neurotrofický rastový faktor a jeho použitie
US6284540B1 (en) 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
EP1137774A2 (en) * 1998-12-09 2001-10-04 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
EP1873244A3 (en) * 1999-06-02 2008-04-02 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
KR20040067841A (ko) * 2000-12-22 2004-07-30 제넨테크, 인크. Ｇｄｎｆ 리간드 족의 구성원인 아르테민의 신규 용도
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US20040077543A1 (en) * 2001-03-28 2004-04-22 Sah Dinah W. Y. Treatment using neublastin polypeptides
EP1395279B1 (en) * 2001-03-28 2011-10-05 Biogen Idec MA Inc. Use of neublastin polypeptides for treating neuropathic pain
CN100411618C (zh) * 2002-05-17 2008-08-20 迪欧加药品公司 有效的选择性阿片受体调制剂化合物的用途
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
ES2479942T3 (es) 2003-04-18 2014-07-25 Biogen Idec Ma Inc. Neublastina glucosilada conjugada con polímero
ATE423134T1 (de) 2003-06-10 2009-03-15 Nsgene As Verbesserte sezernierung von neublastin
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
RS51453B (en) * 2004-08-19 2011-04-30 Biogen Idec Ma Inc. NEUBLASTIN
AU2005277227B2 (en) 2004-08-19 2011-10-06 Biogen Ma Inc. Refolding transforming growth factor beta family proteins
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
WO2007103182A2 (en) * 2006-03-01 2007-09-13 Biogen Idec Ma Inc. Compostions and methods for administering gdnf ligand family proteins
RU2471487C2 (ru) 2007-02-06 2013-01-10 Тай Джун ЙОО Лечение и предупреждение нейродегенеративных заболеваний с использованием генной терапии
JP5583005B2 (ja) 2007-05-01 2014-09-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド 血管新生を増大させるための組成物および方法
AU2008269689A1 (en) * 2007-06-27 2008-12-31 Auckland Uniservices Limited Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
EP2205634A2 (en) * 2007-08-08 2010-07-14 Biogen Idec MA, Inc. Anti-neublastin antibodies and uses thereof
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
US11225689B2 (en) * 2016-08-17 2022-01-18 The Broad Institute, Inc. Method for determination and identification of cell signatures and cell markers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US20020055467A1 (en) * 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
SK287361B6 (sk) * 1998-07-14 2010-08-09 Janssen Pharmaceutica N. V. Ľudský neurotrofický rastový faktor a jeho použitie
US7067473B1 (en) * 1998-07-14 2006-06-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
US6284540B1 (en) * 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
EP1137774A2 (en) † 1998-12-09 2001-10-04 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
JP2002051906A (ja) * 2000-08-11 2002-02-19 Nippon Platec Co Ltd Ｉｈ調理器による加熱を可能にしたアルミ箔材料及びこのアルミ箔材料を用いて成形したアルミ箔材料製食品用容器
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US11162698B2 (en) † 2017-04-14 2021-11-02 Johnson Controls Tyco IP Holdings LLP Thermostat with exhaust fan control for air quality and humidity control

Also Published As

Publication number Publication date
KR100773776B1 (ko) 2007-11-12
CA2333910C (en) 2016-11-15
ES2479067T3 (es) 2014-07-23
NO20010212L (no) 2001-03-14
JP2010158241A (ja) 2010-07-22
NO331809B1 (no) 2012-04-10
SK142001A3 (en) 2002-02-05
CN1342165A (zh) 2002-03-27
CN1243770C (zh) 2006-03-01
NZ509723A (en) 2004-01-30
US20050233359A1 (en) 2005-10-20
HK1045528A1 (en) 2002-11-29
ATE343594T1 (de) 2006-11-15
BG105107A (en) 2001-10-31
HRP20010036B1 (en) 2010-06-30
HUP0102821A2 (hu) 2001-11-28
HUP0102821A3 (en) 2003-09-29
CZ200128A3 (cs) 2001-08-15
ES2275349T3 (es) 2007-06-01
WO2000004050A2 (en) 2000-01-27
CY1105949T1 (el) 2011-04-06
EP1640381A2 (en) 2006-03-29
HU226073B1 (en) 2008-04-28
JP4469500B2 (ja) 2010-05-26
JP4624476B2 (ja) 2011-02-02
SI1640381T1 (sl) 2014-07-31
KR100712223B1 (ko) 2007-04-27
EP1097167A2 (en) 2001-05-09
DE69933771T2 (de) 2007-09-13
PL348431A1 (en) 2002-05-20
CY1115496T1 (el) 2017-01-04
AU768472B2 (en) 2003-12-11
EP1640381B1 (en) 2014-05-14
CZ303868B6 (cs) 2013-06-05
SK287361B6 (sk) 2010-08-09
AU5283299A (en) 2000-02-07
HRP20010036A2 (en) 2001-12-31
CA2333910A1 (en) 2000-01-27
EP1097167B2 (en) 2018-12-12
WO2000004050A3 (en) 2000-11-09
NO20010212D0 (no) 2001-01-12
BRPI9912819B8 (pt) 2021-05-25
EP1097167B1 (en) 2006-10-25
BG65518B1 (bg) 2008-10-31
PL209952B1 (pl) 2011-11-30
KR20060061408A (ko) 2006-06-07
TR200100074T2 (tr) 2001-11-21
DE69933771D1 (de) 2006-12-07
ID27024A (id) 2001-02-22
IL140877A0 (en) 2002-02-10
HK1045528B (zh) 2006-10-27
DK1640381T3 (da) 2014-07-14
HK1092477A1 (en) 2007-02-09
PT1640381E (pt) 2014-07-17
BR9912819A (pt) 2001-05-02
KR20010083108A (ko) 2001-08-31
PT1097167E (pt) 2007-02-28
JP2002520042A (ja) 2002-07-09
US7544788B2 (en) 2009-06-09
BRPI9912819B1 (pt) 2018-09-18
EP1640381A3 (en) 2007-01-31

Similar Documents

Publication Publication Date Title
HK1092477A1 (en) Neurotrophic growth factor
DK0733067T3 (da) N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
EP1832599A3 (en) Albumin fusion proteins
EP2277888A3 (en) Fusion proteins of albumin and erythropoietin
ATE299012T1 (de) Kosmetische zusammensetzung fuer hautregenerierung ohne hautreizung
NL300271I1 (nl) DNA dat humaan papillomavirus type 18 codeert.
ATE388165T1 (de) Menschliches cnp-gen und vorläuferprotein
DE60126602D1 (de) Neue collectine
DE60139113D1 (de) 18477, eine menschliche proteinkinase und deren verwendung
DK1040191T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
DK0919621T3 (da) Human TAK1 og DNA der koder derfor
DE59709066D1 (de) Mittel zur dauerhaften Verformung von menschlichen Haaren
ATE344802T1 (de) Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure
DK0966533T3 (da) Aktivitetsafhængig neurotrof faktor III (ADNF III).
ATE202786T1 (de) Zellwachstum hemmendes protein
WO2002046380A3 (en) Protein kinase
RU92015973A (ru) Средство снижения температуры тела теплокровных животных